A Phase 3 interventional study of Ruxolitinib Cream and Vehicle Cream in Hidradenitis Suppurativa, sponsored by Incyte Corporation. Active, not recruiting at 107 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.
Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one is the 6th largest by enrollment, is one of 4 that started in 2025, is one of 6 in phase 3, and was the 9th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Canada
Ages 12–17
Incyte Corporation · Sites in United States
Ages 12–75
Incyte Corporation · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
By country, each count listing its studies:
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 573 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 391 across the 12 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
2 of the studies in Hidradenitis Suppurativa by Incyte Corporation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT07049575Incyte CorporationStudy to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | 2026-12-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Mild to moderate HS (Hurley I or II) with the following at both screening and baseline visits:
Exclusion Criteria:
Participants received ruxolitinib 1.5% cream, applied topically to the affected area as defined in the protocol.
Drug: Ruxolitinib Cream
Participants received vehicle cream, applied topically to the affected area as defined by the protocol.
Drug: Vehicle Cream
Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baseline
HiSCR75 is defined as at least a 75% reduction from baseline in the total abscess and/or inflammatory nodule (AN) count with no increase from baseline in abscess or draining tunnel count.
Time frame: Week 16
Proportion of participants with ≥ 1 flare
Defined as a ≥ 25% increase in AN count with a minimum increase in total AN count of 2 relative to baseline.
Time frame: Up to 16 weeks
Proportion of participants who achieve HiSCR50
Defined as a ≥ 50 reduction from baseline in total AN count with no increase from baseline in abscess or draining tunnel count.
Time frame: Week 16
Proportion of participants who achieve Skin Pain Numeric Rating Scale (NRS)3 among participants with baseline Skin Pain NRS score ≥ 3
Participants with a Skin Pain score of at least 3 at baseline and who achieve Skin Pain NRS3, defined as at least 3-unit reduction from baseline in the Skin Pain NRS.
Time frame: Week 16
Treatment-IR Population: Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) from baseline
Treatment IR-Population defined as participants who had an inadequate response, intolerance, or contraindication to prior topical or systemic medications for HS. HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count with no increase from baseline in abscess or draining tunnel count.
Time frame: Week 16
Treatment-IR Population: Proportion of participants with ≥ 1 HS flare
Defined as a ≥ 25% increase in total AN count with a minimum increase in AN count of 2 relative to baseline.
Time frame: Up to 16 weeks
Treatment-IR Population: Proportion of participants who achieve Skin Pain Numeric Rating Scale (NRS)3 among participants with baseline Skin Pain NRS score ≥ 3
Participants with a Skin Pain score of at least 3 at baseline and who achieve Skin Pain NRS3, defined as at least 3-unit reduction from baseline in the Skin Pain NRS.
Time frame: Week 16
Proportion of participants who achieve HiSCR50/75/90/100 at each postbaseline visit
Defined as a ≥ 50%/75%/90%/100% reduction from baseline in total AN count with no increase from baseline in abscess or draining tunnel count.
Time frame: Up to 16 weeks
Extension Period: Proportion of participants with ≥ 1 HS flare
Defined as a ≥ 25% increase in total AN count with a minimum increase in AN count of 2 relative to baseline.
Time frame: From Week 16 through Week 52
Proportion of participants who achieve abscess and/or inflammatory nodule (AN)75 at each postbaseline visit
Defined as a ≥ 75% reduction from baseline in total AN count.
Time frame: Up to 52 weeks
Mean change from baseline in total AN count at each postbaseline visit
Defined as mean change in total AN count.
Time frame: Up to 52 weeks
Percentage change from baseline in total AN count at each postbaseline visit
Defined as percent change from baseline in total AN count.
Time frame: Up to 52 weeks
Mean change from baseline in abscess count at each postbaseline visit
Defined as mean change of abscess(es) count relative to baseline.
Time frame: Up to 52 weeks
Percentage change from baseline in abscess count at each postbaseline visit
Percent Change from baseline in number of abscess(es).
Time frame: Up to 52 weeks
Mean change from baseline in inflammatory nodule count at each postbaseline visit
Defined as mean change of inflammatory nodule count relative to baseline.
Time frame: Up to 52 weeks
Percentage change from baseline in inflammatory nodule count at each postbaseline visit
Defined as percent change from baseline in number of inflammatory nodule(s).
Time frame: Up to 52 weeks
Proportion of participants with presence of draining tunnels at each postbaseline visit
Participants with presence of draining tunnels.
Time frame: Up to 52 weeks
Proportion of participants who achieve Skin Pain Numeric Rating Scale (NRS)3 among participants with baseline Skin Pain NRS score ≥ 3 at each postbaseline visit
Participants with a Skin Pain score of at least 3 at baseline and who achieve Skin Pain NRS3, defined as at least 3-unit reduction from baseline in the Skin Pain NRS.
Time frame: Up to 52 weeks
Proportion of participants who achieve Itch Numeric Rating Scale (NRS)30 among participants with baseline Itch NRS score ≥ 3 at each postbaseline visit
Participants with a Itch score of at least 3 at baseline and who achieve Itch NRS30, defined as at least a 30% reduction and at least 1-unit reduction from baseline in the Itch NRS.
Time frame: Up to 52 weeks
Proportion of participants who achieve Patient Global Impression of Change (PGIC) at each postbaseline visit
The PGIC is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.
Time frame: Up to 52 weeks
Proportion of participants who achieve PGIC score 1 or 2 at each postbaseline visit
The PGIC is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.
Time frame: Up to 52 weeks
Patient Global Impression of Severity (PGIS) score at each postbaseline visit
The PGIS is a single-item, self-reporting measure in which the participant rates the severity of their overall status over the past week based on a 5-point scale: (1) none, (2) mild, (3) moderate, (4) severe, and (5) very severe.
Time frame: Up to 52 weeks
Change from baseline in PGIS Score at each postbaseline visit
The PGIS is a single-item, self-reporting measure in which the participant rates the severity of their overall status over the past week based on 5-point scale: (1) none, (2) mild, (3) moderate, (4) severe, and (5) very severe.
Time frame: Up to 52 weeks
Proportion of participants who achieve status of Dermatology Life Quality Index (DLQ1)4 at each postbaseline visit
Defined as a ≥ 4-point reduction in DLQI score relative to baseline. The DLQI is a simple, 10-question, validated questionnaire to measure how much a skin problem has affected an adult participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment.
Time frame: Up to 52 weeks
Proportion of participants who achieve status of Children's Dermatology Life Quality Index (CDLQ1)6 at each postbaseline visit
Defined as a ≥ 6-point reduction in CDLQI score relative to baseline. The CDLQI is a 10-question, validated questionnaire to measure the impact of skin disease on the lives of children over the previous 7 days.
Time frame: Up to 52 weeks
Change from baseline in Hidradenitis Suppurativa Quality of Life (HiSQoL) score at each postbaseline visit
The HiSQoL is a 17-item, HS-specific, health-related, quality-of-life instrument with a 7-day recall period used to assess HS symptoms and the impact of HS problems on quality of life.
Time frame: Up to 52 weeks
Percent change from baseline in Hidradenitis Suppurativa Quality of Life (HiSQoL) score at each postbaseline visit
The HiSQoL is a 17-item, HS-specific, health-related, quality-of-life instrument with a 7-day recall period used to assess HS symptoms and the impact of HS problems on quality of life.
Time frame: Up to 52 weeks
Change from baseline in Hidradenitis Suppurativa Quality of Life - Adolescent (HiSQoL-AA) at each postbaseline visit
The HiSQoL-AA is a 15-item instrument with a 7-day recall period used to assess HS symptoms and experiences of HS in adolescent.
Time frame: Up to 52 weeks
Percent change from baseline in Hidradenitis Suppurativa Quality of Life - Adolescent (HiSQoL-AA) at each postbaseline visit
The HiSQoL-AA is a 15-item instrument with a 7-day recall period used to assess HS symptoms and experiences of HS in adolescent.
Time frame: Up to 52 weeks
Change from baseline in EuroQol 5-dimension 5-level scale (EQ-5D-5L) score at each postbaseline visit
The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome.
Time frame: Up to 52 weeks
Treatment-IR Population: Change from baseline in total abscess count at each postbaseline visit
Defined as change from baseline in total abscess count.
Time frame: Up to 52 weeks
Treatment-IR Population: Percent change from baseline in total abscess count at each postbaseline visit
Percent Change from baseline in total abscess count.
Time frame: Up to 52 weeks
Treatment-IR Population: Change from baseline in total inflammatory nodule count at each postbaseline visit
Defined as change from baseline in total number of inflammatory nodule(s).
Time frame: Up to 52 weeks
Treatment-IR Population: Percent change from baseline in total inflammatory nodule count at each postbaseline visit
Defined as percent change from baseline in number of inflammatory nodule(s).
Time frame: Up to 52 weeks
Treatment-IR Population: Proportion of participants with presence of draining tunnels at each postbaseline visit
Participants with presence of draining tunnels.
Time frame: Up to 52 weeks
Number of Treatment Emergent Adverse Events (TEAEs)
A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first application of study cream.
Time frame: Up to 56 weeks
Showing the first 100 of 107 sites across 9 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Jun 2025 to primary completion in Oct 2026, 15 months.
Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib